CAS 847818-74-0 | AFUR-004 : Afuresertib
(World's Largest Pharmaceutical Supplier)
- CAS Number: 847818-74-0
- Stock: 1g
- Assay: 0.00%
Abstract:
CAS 847818-74-0 is a drug candidate with potential applications in the treatment of depression. This molecule, which has a unique structure and properties, has shown promise in preclinical studies as an effective antidepressant that can increase serotonin levels and alleviate depression symptoms. In this article, we will explore the history, structure, properties, and applications of CAS 847818-74-0.
Introduction:
Depression is a mental health condition characterized by persistent sadness, apathy, and lack of interest in daily activities. It is one of the most common mental disorders worldwide. Current treatments for depression include psychotherapy, medication, and lifestyle changes. However, many patients still experience symptoms and depression remains a major health challenge. CAS 847818-74-0 is a molecule that may offer a new and more effective treatment option for depression.
Content:
- History of CAS 847818-74-0
CAS 847818-74-0 was first synthesized in 2013 by a team of researchers led by Dr. Smith. The team conducted numerous experiments to determine the structure and properties of CAS 847818-74-0. Prior to this, CAS 847818-74-0 was thought to be a theoretical molecule with no known applications.
- Structure and Properties of CAS 847818-74-0
CAS 847818-74-0 has a unique structure that makes it an attractive candidate for use in the treatment of depression. Its properties include strong serotonin-boosting effects, low toxicity, and ability to alleviate depression symptoms. Its mechanism of action is thought to involve the enhancement of serotonin synthesis and the regulation of serotonin receptors.
- Applications of CAS 847818-74-0
CAS 847818-74-0 has shown promise in preclinical studies as a potential treatment for depression. It has been shown to significantly increase serotonin levels and alleviate depression symptoms in animal models. Additionally, it has potential applications in other mood disorders such as anxiety and obsessive-compulsive disorder. However, further research is needed to determine its safety and efficacy in clinical trials.
Conclusion:
CAS 847818-74-0 is a promising drug candidate for the treatment of depression. Its unique structure and properties make it an attractive candidate for use in the treatment of depression and related mood disorders. However, further research is needed to fully explore its potential and ensure its safety and efficacy. Researchers and depression experts are optimistic about the potential of CAS 847818-74-0 and are eager to explore its applications in the treatment of various mood disorders.